Investing.com - Financial Markets Worldwide

Shanghai Labway Clinical Laboratory Co Ltd (301060)

Shenzhen
Currency in CNY
10.77
+0.29(+2.77%)
Closed·

301060 Financial Summary

Key Ratios

P/E Ratio-35.19
Price/Book2.49
Debt / Equity14.48%
Return on Equity-5.63%
Dividend Yield1.86%
EBITDA-2.73M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2022
01/01
2023
01/01
2023
31/12
2024
31/12
Income Statement
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa1,238.191,778.334,199.311,674.371,742.18
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa395.22672.91,779.32329.31332.53
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa158.18294.151,070.98-155.55-62.37
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa110.38203.84617.32-141.59-109.44
Balance Sheet
Total Assets
aa.aaaa.aaaa.aaaa.aaaa.aa1,471.512,105.493,746.872,986.862,623.33
Total Current Liabilities
aa.aaaa.aaaa.aaaa.aaaa.aa218.01412.981,413.82822.83615.59
Total Equity
aa.aaaa.aaaa.aaaa.aaaa.aa1,247.381,639.812,272.751,980.161,820.34
Cash Flow
Levered Free Cash Flow
aa.aaaa.aaaa.aaaa.aaaa.aa112.4238.83-378.79207.16187.85
Cash from Operations
aa.aaaa.aaaa.aaaa.aaaa.aa167.87223.5184.17546.99216.31
Cash from Investing
aa.aaaa.aaaa.aaaa.aaaa.aa83.72-403.41180.05-398.5-68.58
Cash from Financing
aa.aaaa.aaaa.aaaa.aaaa.aa-96.11119.7550.4844.73-180.25
Net Change in Cash
aa.aaaa.aaaa.aaaa.aaaa.aa155.25-60.12314.15192.65-32.52
* In Millions of CNY (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS -0.29%
Dividend Yield
1.86%
Industry Median 1.87%
Annualised payout
0.20
Paid annually
5-Years Growth
-
Growth Streak
Unlock

Earnings

Latest Release
Apr 27, 2025
EPS / Forecast
-0.02 / --
Revenue / Forecast
350.88M / --
EPS Revisions
a
a
Unlock
Last 90 days

FAQ

What were Shanghai Labway Clinical Laboratory's earnings for the latest quarter?

The Shanghai Labway Clinical Laboratory EPS (TTM) is -0.29. Shanghai Labway Clinical Laboratory reported sales of 350.88, net income of -8.08, and EPS of -0.02 for the latest quarter.

What was Shanghai Labway Clinical Laboratory's net income for the latest quarter?

Shanghai Labway Clinical Laboratory's net income for the latest quarter was -8.08.

How did Shanghai Labway Clinical Laboratory's performance compare year-over-year in the latest quarter?

The company's revenue moved from 422.15 in the previous quarter to 350.88 in the latest quarter, and net income moved from -68.85 to -8.08 compared to the previous quarter.

What is Shanghai Labway Clinical Laboratory's net profit margin on a TTM basis?

Shanghai Labway Clinical Laboratory's trailing twelve months (TTM) net profit margin is -6.28%.

How does Shanghai Labway Clinical Laboratory's debt to equity ratio compare to industry standards?

Shanghai Labway Clinical Laboratory's total debt-to-equity ratio is 14.48%.

What is Shanghai Labway Clinical Laboratory's return on investment on a TTM basis?

Shanghai Labway Clinical Laboratory's trailing twelve months (TTM) return on investment (ROI) is -5.63%.

Did Shanghai Labway Clinical Laboratory gain or lose cash last quarter?

In the latest quarter, Shanghai Labway Clinical Laboratory's net change in cash was -83.61 million.

What were Shanghai Labway Clinical Laboratory's total assets and liabilities in the latest quarter?

As of the latest quarter, Shanghai Labway Clinical Laboratory reported total assets of 2,616.25 million and total liabilities of 630.32 million.

How has Shanghai Labway Clinical Laboratory's total revenue grown this year?

Shanghai Labway Clinical Laboratory's total revenue was 422.15 in the previous quarter and 350.88 in the latest quarter.

What is Shanghai Labway Clinical Laboratory's gross margin on a TTM basis?

Shanghai Labway Clinical Laboratory's trailing twelve months (TTM) gross margin is 18.53%.

What was Shanghai Labway Clinical Laboratory's revenue per share for the latest quarter?

Shanghai Labway Clinical Laboratory's revenue per share for the latest quarter was 6.47.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.